1
|
Basu A, Seth S, Chauhan AK, Bansal N, Arora K, Mahaur A. Comparative study of tumor markers in patients with colorectal carcinoma before and after chemotherapy. Ann Transl Med 2016; 4:71. [PMID: 27004218 DOI: 10.3978/j.issn.2305-5839.2016.02.02] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
BACKGROUND Colorectal carcinoma (CRC), the second leading cause of cancer-related deaths in US, has a rising time-trend in India. Tumour markers in CRC are extensively researched, and there's still debate on their diagnostic and prognostic values. METHODS In this hospital-based longitudinal study in north India, 51 male diagnosed CRC cases (pre-chemotherapy) were contrasted against 50 age and sex matched controls. Nine biomarkers: carcinoembryonic antigen (CEA), prolactin (PRL), alfa feto protein (AFP), total human chorionic gonadotropin (hCG), cancer antigen-125 (CA-125), serum testosterone, prostate specific antigen (PSA) and ferritin were measured by direct chemiluminescence technique. Further, follow-up was done on 47 cases after treatment with six cycles of 5-flurouracil (5-FU) and oxaliplatin. RESULTS Mean serum CEA (case: 5.94±8.27 ng/mL, control: 2.5±0.79 ng/mL, P<0.05), PRL (case: 28.12±13.39 ng/mL, control: 14.24±13.13 ng/mL, P<0.0001), AFP (case: 10.9±6.65 ng/mL, control: 4.02±1.26 ng/mL, P<0.0001) levels were significantly raised in CRC cases compared to controls. On the contrary, mean testosterone level (P<0.05) was lower among the cases. After chemotherapy, the mean serum CEA (P<0.05), AFP (P<0.0001) and CA-125 (P<0.05) levels among the cases decreased significantly compared to their pretreatment levels. CONCLUSIONS The present study strongly indicates the role of CEA, PRL, AFP, CA-125 and testosterone as important biomarkers in male CRC patients from north India. Further, AFP, CA-125 and CEA may be used to assess the effectiveness of chemotherapy in such patients.
Collapse
Affiliation(s)
- Atreyee Basu
- 1 Department of Biochemistry, Post Graduate Institute of Medical Sciences (PGIMS), Rohtak, Haryana, India ; 2 Department of Radiotherapy, Post Graduate Institute of Medical Sciences (PGIMS), Rohtak, Haryana, India ; 3 Department of Biochemistry, VMMC and Safdarjung Hospital, New Delhi, India
| | - Shashi Seth
- 1 Department of Biochemistry, Post Graduate Institute of Medical Sciences (PGIMS), Rohtak, Haryana, India ; 2 Department of Radiotherapy, Post Graduate Institute of Medical Sciences (PGIMS), Rohtak, Haryana, India ; 3 Department of Biochemistry, VMMC and Safdarjung Hospital, New Delhi, India
| | - Ashok K Chauhan
- 1 Department of Biochemistry, Post Graduate Institute of Medical Sciences (PGIMS), Rohtak, Haryana, India ; 2 Department of Radiotherapy, Post Graduate Institute of Medical Sciences (PGIMS), Rohtak, Haryana, India ; 3 Department of Biochemistry, VMMC and Safdarjung Hospital, New Delhi, India
| | - Nupur Bansal
- 1 Department of Biochemistry, Post Graduate Institute of Medical Sciences (PGIMS), Rohtak, Haryana, India ; 2 Department of Radiotherapy, Post Graduate Institute of Medical Sciences (PGIMS), Rohtak, Haryana, India ; 3 Department of Biochemistry, VMMC and Safdarjung Hospital, New Delhi, India
| | - Kanchan Arora
- 1 Department of Biochemistry, Post Graduate Institute of Medical Sciences (PGIMS), Rohtak, Haryana, India ; 2 Department of Radiotherapy, Post Graduate Institute of Medical Sciences (PGIMS), Rohtak, Haryana, India ; 3 Department of Biochemistry, VMMC and Safdarjung Hospital, New Delhi, India
| | - Anuradha Mahaur
- 1 Department of Biochemistry, Post Graduate Institute of Medical Sciences (PGIMS), Rohtak, Haryana, India ; 2 Department of Radiotherapy, Post Graduate Institute of Medical Sciences (PGIMS), Rohtak, Haryana, India ; 3 Department of Biochemistry, VMMC and Safdarjung Hospital, New Delhi, India
| |
Collapse
|
2
|
Thorpe JD, Duan X, Forrest R, Lowe K, Brown L, Segal E, Nelson B, Anderson GL, McIntosh M, Urban N. Effects of blood collection conditions on ovarian cancer serum markers. PLoS One 2007; 2:e1281. [PMID: 18060075 PMCID: PMC2093996 DOI: 10.1371/journal.pone.0001281] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2007] [Accepted: 11/09/2007] [Indexed: 01/09/2023] Open
Abstract
BACKGROUND Evaluating diagnostic and early detection biomarkers requires comparing serum protein concentrations among biosamples ascertained from subjects with and without cancer. Efforts are generally made to standardize blood processing and storage conditions for cases and controls, but blood sample collection conditions cannot be completely controlled. For example, blood samples from cases are often obtained from persons aware of their diagnoses, and collected after fasting or in surgery, whereas blood samples from some controls may be obtained in different conditions, such as a clinic visit. By measuring the effects of differences in collection conditions on three different markers, we investigated the potential of these effects to bias validation studies. METHODOLOGY AND PRINCIPLE FINDINGS We analyzed serum concentrations of three previously studied putative ovarian cancer serum biomarkers-CA 125, Prolactin and MIF-in healthy women, women with ovarian cancer undergoing gynecologic surgery, women undergoing surgery for benign ovary pathology, and women undergoing surgery with pathologically normal ovaries. For women undergoing surgery, a blood sample was collected either in the clinic 1 to 39 days prior to surgery, or on the day of surgery after anesthesia was administered but prior to the surgical procedure, or both. We found that one marker, prolactin, was dramatically affected by collection conditions, while CA 125 and MIF were unaffected. Prolactin levels were not different between case and control groups after accounting for the conditions of sample collection, suggesting that sample ascertainment could explain some or all of the previously reported results about its potential as a biomarker for ovarian cancer. CONCLUSIONS Biomarker validation studies should use standardized collection conditions, use multiple control groups, and/or collect samples from cases prior to influence of diagnosis whenever feasible to detect and correct for potential biases associated with sample collection.
Collapse
Affiliation(s)
- Jason D Thorpe
- Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Abstract
BACKGROUND Colorectal cancer is a common malignancy of the gastrointestinal tract. It is the second cancer cause of death in females and third in males. Production of prolactin has been reported with several tumours. However, elevated prolactin plasma levels in colorectal cancer patients remained unclear. METHODS In this cross sectional study serum prolactin and carcinoembryonic antigen (CEA) concentrations were assayed using immunoradiometric assay kits, preoperatively in 47 patients, and the results were compared with 51 age and sex matched controls. RESULTS Prolactin and CEA concentration in patients were significantly more as compared with controls. Hyperprolactinemia was found in 36 (76.6%) patients, while 28 (59.6%) had high level of CEA. CONCLUSIONS Prolactin may be a better tumour marker than CEA in patients with colorectal malignancy.
Collapse
Affiliation(s)
- Ahmad Reza Soroush
- Department of surgery, Tehran University of Medical Sciences, Shariati hospital, kargar shomali st, Tehran 14114, Iran
- Research Development Centre, Tehran University of Medical Sciences, Shariati hospital, kargar shomali st, Tehran 14114, Iran
| | - Hosein Mahmood zadeh
- Department of surgery, Tehran University of Medical Sciences, Shariati hospital, kargar shomali st, Tehran 14114, Iran
| | - Mehrnush Moemeni
- Research Development Centre, Tehran University of Medical Sciences, Shariati hospital, kargar shomali st, Tehran 14114, Iran
| | - Behnam Shakiba
- Students' Scientific Research Centre (SSRC), Tehran University of Medical Sciences, Tehran, Iran
| | - Sara Elmi
- Students' Scientific Research Centre (SSRC), Tehran University of Medical Sciences, Tehran, Iran
| |
Collapse
|